Source-grounded facts extracted from Lineage Cell Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on the compensation paid to the Company’s named executive officers at the 2026-06-10 meeting.
“3. Shareholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the following votes:”
Lineage Cell Therapeutics, Inc. shareholders approved Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“2. Shareholders ratified the appointment of Baker Tilly US, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Lineage Cell Therapeutics, Inc. shareholders approved Election of seven nominees to the board of directors at the 2026-06-10 meeting.
“1. Shareholders elected the seven nominees named below to the Company’s board to hold office until the Company’s 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Lineage Cell Therapeutics, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 12, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter ended March 31, 2026”
Lineage Cell Therapeutics, Inc. reported financial results for quarter and year ended December 31, 2025.
“On March 5, 2026, Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2025”
Lineage Cell Therapeutics, Inc. engaged Baker Tilly US, LLP as its auditor.
“the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
Moss Adams LLP resigned as auditor of Lineage Cell Therapeutics, Inc..
“In connection with the notification of the merger, Moss Adams resigned as the auditors of the Company”
Lineage Cell Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $1.4 million.
“Total revenues for the three months ended March 31, 2024 were approximately $1.4 million”
Lineage Cell Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc. (effective 2024-03-22).
“on March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent.”
Lineage Cell Therapeutics, Inc. reported year ended December 31, 2023 results: revenue $8.9 million.
“Total revenues for the year ended December 31, 2023 were $8.9 million, a decrease of $5.8 million as compared to $14.7 million for the same period in 2022.”
Lineage Cell Therapeutics, Inc. reported three months ended December 31, 2023 results: revenue approximately $2.1 million, net income $4.8 million, EPS $0.03 per share (basic and diluted).
“Revenues: Lineage’s revenue is generated primarily from collaboration revenues and royalties. Total revenues for the three months ended December 31, 2023 were approximately $2.1 million, a net increase of $0.2 million as compared to $1.9 million for the same period in 2022. Operating Expenses: Operating expenses are comprised of research and development (“R&D”)”
Lineage Cell Therapeutics, Inc. entered into purchase agreement with certain investors valued at $14.0 million (effective 2024-02-06).
“On February 6, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”) entered into a stock purchase agreement (the “purchase agreement”) with certain investors relating to the purchase and sale in a registered direct offering of an aggregate of 13,461,540 common shares of the Company.”
Lineage Cell Therapeutics, Inc. reported the three months ended September 30, 2023 results: revenue $1.2 milli.
“revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2023 were $1.2 milli”
Lineage Cell Therapeutics, Inc. shareholders approved Adjournment of Annual Meeting to solicit additional proxies if necessary for Proposal 6 at the 2023-09-06 meeting.
“Proposal 7. The Company’s shareholders approved the adjournment of the Annual Meeting, if necessary or advisable, to solicit additional proxies in favor of Proposal 6 in the event there are not sufficient votes to approve Proposal 6 by the votes set forth below.”
Lineage Cell Therapeutics, Inc. shareholders approved Amendment to restated articles of incorporation to increase authorized common shares from 250,000,000 to 450,000,000 at the 2023-09-06 meeting.
“Proposal 6. The Company’s shareholders approved an amendment to the Company’s restated articles of incorporation to increase the number of authorized common shares from 250,000,000 to 450,000,000 by the votes set forth below.”
Lineage Cell Therapeutics, Inc. shareholders approved Approval of amendment to 2021 Equity Incentive Plan to increase shares by 19,500,000 at the 2023-09-06 meeting.
“Proposal 5. The Company’s shareholders approved the EIP Amendment by the votes set forth below.”
Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on frequency of holding advisory vote on executive compensation at the 2023-09-06 meeting.
“Proposal 4. The Company’s shareholders voted as follows with respect to the preferred frequency of holding an advisory vote on the compensation of the Company’s named executive officers.”
Lineage Cell Therapeutics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-09-06 meeting.
“Proposal 3. The Company’s shareholders approved, on an advisory and non-binding basis, the compensation paid to the Company’s named executive officers, as set forth in the Proxy Statement, by the votes set forth below.”
Lineage Cell Therapeutics, Inc. shareholders approved Ratification of WithumSmith+Brown, PC as independent registered public accounting firm for fiscal year 2023 at the 2023-09-06 meeting.
“Proposal 2. The Company’s shareholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the votes set forth below.”
Lineage Cell Therapeutics, Inc. shareholders approved Election of nine nominees to the board of directors at the 2023-09-06 meeting.
“Proposal 1. The Company’s shareholders elected the nine nominees named below to the Company’s board of directors to hold office until the Company’s 2024 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Lineage Cell Therapeutics, Inc. reported second quarter ended June 30, 2023 results: revenue $3.2 million.
“revenue is generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended June 30, 2023 were $3.2 million, a net decrease of $1.4 million as compared to approximately $4.6 million for the same period in 2022. The decrease was primarily driven by less collaboration and licensing”
Lineage Cell Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
“Lineage Cell Therapeutics, Inc. issued a press release announcing financial results for the quarter and year ended December 31, 2022, a copy of which is furnished as Exhibit 99.1.”
Lineage Cell Therapeutics, Inc. reported the third quarter of 2022 results: revenue approximately $3.0 million.
“generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021. The increase was driven by collaboration and licensing revenue recognized from deferred”
Jill A. Howe was appointed as Chief Financial Officer at Lineage Cell Therapeutics, Inc..
“On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.”
Lineage Cell Therapeutics, Inc. entered into Stipulation and Agreement of Compromise and Settlement valued at $10.65 million (effective 2022-10-26).
“On October 26, 2022, a Stipulation and Agreement of Compromise and Settlement (the “Settlement Agreement”) was entered into by the plaintiff, on behalf of himself and all others similarly situated, Lineage, and Messrs. Mulroy, Kingsley, LeBuhn and Mohanty.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.